The Role of IL5 in Epithelial Cell Integrity

Who can take part

• (1) sinonasal inflammation for greater than 12 weeks which include at least 2 of the following symptoms: nasal obstruction/congestion, nasal discharge (anterior or posterior), facial pressure/pain, reduction of sense of smell
• (2) confirmation of the clinical symptoms by: (2a) CT scan evidence of paranasal sinus mucosal inflammation, and/or (2b) endoscopic exam evidence of purulence from the sinuses or ostiomeatal complex; and
• (3) presence of nasal polyps seen on endoscopic exam or sinus CT scan

Who cannot take part

• 7. exposure to oral or systemic IV glucocorticoids within 2 weeks of surgery
• 8. exposure to immunomodulatory biologics will be excluded. These include, but are not limited to systemic treatment with biologics omalizumab, dupilumab, mepolizumab, benralizumab, reslizumab, or rituximab
• 6. disease secondary to a clearly defined anatomic process, such as facial trauma, and obstruction due to sinonasal neoplasm
• 1. Children under the age of 18 will be excluded due to:; possible confounding diagnosis of cystic fibrosis and other non-Type 2 inflammatory etiologies that commonly presents with nasal polyps in the pediatric population; lack of complete pneumatization of the majority of paranasal sinuses
• 2. pregnant or lactating females,
• 3. prisoners,
• 4. mentally disabled
• 5. persons unable to give informed consent will be contemplated for inclusion